# Noema Pharma

> Noema Pharma is a Basel-based clinical-stage biotech building first-in-disease oral small-molecule therapeutics for central nervous system disorders. Founded in 2019 by Sofinnova Partners around four mid-stage assets in-licensed from Roche, the company targets overlooked neurological conditions - from seizures in tuberous sclerosis complex and pain in trigeminal neuralgia to Tourette syndrome and CNS-mediated symptoms of menopause. It has raised roughly CHF 130 million (about USD 147 million) in Series B financing from a syndicate including Forbion, Jeito Capital, Sofinnova, EQT Life Sciences and UPMC Enterprises.

- **Founded:** 2019
- **Headquarters:** Basel, Switzerland
- **Founders:** Sofinnova Partners (Founding investor / company creator), George Garibaldi (Co-founder (former Roche head of neuroscience product development)), Luigi Costa (Co-founder and founding CEO)
- **Team size:** Approximately 34 employees
- **Products:** Basimglurant (NOE-101), Gemlapodect (NOE-105), NOE-115
- **Notable:** Raised roughly USD 168 million total, including a CHF 130 million (USD 147 million) Series B, Built four clinical-stage CNS programs from assets in-licensed from Roche, Advanced three programs into active Phase 2 trials with readouts expected in 2025

## Products & services

- **Basimglurant (NOE-101)** — An mGluR5 negative allosteric modulator in Phase 2 trials for severe pain in trigeminal neuralgia and seizures in tuberous sclerosis complex.
- **Gemlapodect (NOE-105)** — A PDE10a inhibitor in Phase 2b development for Tourette syndrome; also explored in childhood-onset fluency disorder (stuttering).
- **NOE-115** — A broad-spectrum monoamine modulator in Phase 2 for vasomotor symptoms and other CNS-mediated symptoms of menopause.

## Achievements

- Raised roughly USD 168 million total, including a CHF 130 million (USD 147 million) Series B
- Built four clinical-stage CNS programs from assets in-licensed from Roche
- Advanced three programs into active Phase 2 trials with readouts expected in 2025
- Attracted a top-tier investor syndicate including Forbion, Jeito, EQT Life Sciences and UPMC Enterprises
- Recruited CEO Ilise Lombardo, who previously co-built Arvelle Therapeutics (acquired by Angelini Pharma for ~USD 1 billion)

## Latest updates

- **2024-12** — Closed Series B extension led by EQT Life Sciences, bringing total Series B financing to CHF 130 million (USD 147 million) to fund Phase 2 trials.
- **2023-06** — Appointed Ilise Lombardo, M.D., as Chief Executive Officer, succeeding co-founder Luigi Costa.
- **2023-03** — Raised CHF 103 million (USD 112 million) Series B led by Forbion and Jeito Capital.

## Links

- Website: https://noemapharma.com
- LinkedIn: https://www.linkedin.com/company/noema-pharma-ag

---

Profile page: https://yespress.io/noema-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-06-13